Dapagliflozin is a first-in-class, oral, once-daily, selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2). The drug is indicated monotherapy as well as part of combination therapy to improve glycaemic control. Additional benefits include weight loss and blood pressure reduction, as an adjunct to diet and exercise in adults with type 2 diabetes mellitus (T2DM).
Dapagliflozin’s safety and efficacy was assessed in the DECLARE-TIMI 58 trial (n=17,160), which randomised patients 1:1 to either dapagliflozin 10 mg (n=8,582) or matching placebo (n=8,578). The mean age of the participants was 64, 37% was female, and the duration of follow-up was 4.2 years . A distinguishing feature of DECLARE-TIMI 58 relative to other SGLT2i trials was the large population of patients without established cardiovascular disease (59.3%).
Dapagliflozin in peripheral artery disease patients
In 2018, dapagliflozin was shown to be superio...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Letter from the Editor Next Article
Substantial impact of temporary interruptions of warfarin versus DOAC »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.